康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

未开盘 12-19 16:08:47

3.510

-0.090

-2.50%

最高3.550	最低3.450	成交量185.20万
今开3.530	昨收3.600	日振幅2.78%
总市值33.77亿	流通市值33.77亿	总股本9.62亿
成交额648.67万	换手率0.19%	流通股本9.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":3.51,"timestamp":1734595727022,"preClose":3.6,"halted":0,"volume":1852000,"delay":0,"floatShares":961999999,"shares":961999999,"eps":-0.23534414,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.09,"latestTime":"12-19 16:08:47","open":3.53,"high":3.55,"low":3.45,"amount":6486717,"amplitude":0.027778,"askPrice":3.51,"askSize":4000,"bidPrice":3.5,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-0.2462837510458624,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1576080000000,"adjPreClose":3.6,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.465693,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966/wiki","defaultTab":"wiki","newsList":[{"id":"2492975799","title":"康宁杰瑞制药－Ｂ(09966)股价上升5.882%，现价港币$3.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2492975799","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492975799?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:30","pubTimestamp":1734507000,"startTime":"0","endTime":"0","summary":"[上升股]康宁杰瑞制药－Ｂ(09966) 股价在下午03:30比前收市价上升5.882%，现股价为港币$3.6。至目前为止，今日最高价为$3.6，而最低价为$3.4。总成交量为211.5万股，总成交金额为港币$746.654万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2412181423/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2492734759","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超5% 多产品进入商业化和注册临床阶段 机构指其处于相对低估水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2492734759","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492734759?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:25","pubTimestamp":1734506709,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超5%，截至发稿，涨5.59%，报3.59港元，成交额741.26万港元。KN026已进入到注册临床阶段，预计2025年递交NDA；JSKN003 已启动注册临床，HER2双表位双抗ADC有望成为HER2领域终极解决方案；JSKN033初步数据亮相国际学术大会，IO+ADC皮下组合未来多种适应症临床开发潜力。中泰证券指出，康宁杰瑞制药处于相对低估的水平，首次覆盖，给予“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2492474509","title":"康宁杰瑞制药-B盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492474509","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492474509?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:58","pubTimestamp":1734490733,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘10时58分，康宁杰瑞制药-B股票出现波动，股价大幅拉升5.00%。截至发稿，该股报3.570港元/股，成交量72.4万股，换手率0.08%，振幅5.00%。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为0.44%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的肿瘤单克隆抗体、双特异性抗体及ADCs组成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218105854984c9ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218105854984c9ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2491165997","title":"康宁杰瑞制药-B12月16日遭主力抛售99万元 环比增加160.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491165997","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491165997?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:16","pubTimestamp":1734337011,"startTime":"0","endTime":"0","summary":"12月16日, 康宁杰瑞制药-B股价跌7.59%，报收3.41元，成交金额1613万元，换手率0.48%，振幅7.32%，量比1.22。康宁杰瑞制药-B今日主力资金净流出99万元，上一交易日主力净流出38万元，今日环比增加160.53%。该股近5个交易日下跌11.89%，主力资金累计净流出300万元；近20日主力资金累计净流出50万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161734a1f27aaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161734a1f27aaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2491691689","title":"康宁杰瑞制药-B(09966)下跌5.15%，报3.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491691689","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491691689?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:41","pubTimestamp":1734313299,"startTime":"0","endTime":"0","summary":"12月16日，康宁杰瑞制药-B(09966)盘中下跌5.15%，截至09:41，报3.5元/股，成交158.58万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16094146408093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2491168646","title":"康宁杰瑞制药-B盘中异动 大幅下跌5.15%报3.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491168646","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491168646?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:41","pubTimestamp":1734313292,"startTime":"0","endTime":"0","summary":"2024年12月16日早盘09时41分，康宁杰瑞制药-B股票出现波动，股价大幅下挫5.15%。截至发稿，该股报3.500港元/股，成交量44.4万股，换手率0.05%，振幅4.34%。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为0.16%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的肿瘤单克隆抗体、双特异性抗体及ADCs组成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094132ab7afff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094132ab7afff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2491685330","title":"广州生物岛告欠租900万明星企业，催租“紧箍咒”备受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2491685330","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491685330?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:09","pubTimestamp":1734311345,"startTime":"0","endTime":"0","summary":"前言：有消息传出，今年以来，广州生物岛已起诉一批欠租企业。南都记者登录广州海珠区法院检索开庭公告后发现，至少有七家企业涉及租赁合同纠纷，被广州国际生物岛集团有限公司（下简称“生物岛集团”）起诉。而中国裁判文书网上的信息显示，此前因欠租而被生物岛集团起诉的企业不过是两三家而已。在这批因欠租而被起诉的企...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/O-yX9WIzQsR8OGIoXyvw79W6ki0ky3Ieb37CFMuceS3NQAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O-yX9WIzQsR8OGIoXyvw79W6ki0ky3Ieb37CFMuceS3NQAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241216A023LU00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241216A023LU00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4561","W","BK1258","BK4122","09983","02616","BK1161","BK1542","BK4585","BK1574","BK1229","06958","BK4524","09966","01971","BK4588","BK1583","BK4178","BK4548"],"gpt_icon":0},{"id":"2491345851","title":"康宁杰瑞制药－Ｂ(09966)出现大手卖出87.5万股，成交价$3.69，涉资322.875万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491345851","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491345851?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:08","pubTimestamp":1734077280,"startTime":"0","endTime":"0","summary":"[大手成交]康宁杰瑞制药－Ｂ(09966)在下午04:08出现大手卖出，成交量为87.5万，成交价为港币$3.69，涉资322.875万。至目前为止，股价跌0.27%，今日最高价为$3.71，而最低价为$3.51，总成交量为550.1万股，总成交金额港币$1.979千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2412136795/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2491348631","title":"康宁杰瑞制药-B盘中异动 股价大跌5.14%报3.510港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491348631","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491348631?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:57","pubTimestamp":1734076662,"startTime":"0","endTime":"0","summary":"2024年12月13日临近收盘15时57分，康宁杰瑞制药-B股票出现波动，股价大幅跳水5.14%。截至发稿，该股报3.510港元/股，成交量460.1万股，换手率0.48%，振幅5.41%。资金方面，该股资金流入444.887万港元，流出1003.19万港元。康宁杰瑞制药-B股票所在的生物技术行业中，整体跌幅为1.07%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213155742a1eb5cf3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213155742a1eb5cf3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2487557375","title":"康宁杰瑞制药-B(09966)11月29日斥资227.56万港元回购60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487557375","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487557375?lang=zh_cn&edition=full","pubTime":"2024-11-29 20:33","pubTimestamp":1732883604,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2024年11月29日该公司斥资227.56万港元回购60万股，回购价格为每股3.78-3.80港元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2486624133","title":"港股收盘(11.28) | 恒指收跌1.2% 科网、医药、消费股等承压 吉利汽车(00175)逆势涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486624133","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486624133?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:33","pubTimestamp":1732782788,"startTime":"0","endTime":"0","summary":"蓝筹股表现吉利汽车逆势走高。截至收盘，涨4.87%，报13.78港元，成交额18.74亿港元，贡献恒指6.3点。据港交所权益披露文件，吉利汽车董事会主席李书福在11月26日、11月27日合计购买2420万股吉利汽车股票，如按均价测算，耗资约3.16亿港元，持股从41.19%升至41.40%。黄志达股权权益由11.87%增至12.26%。当月初，其持股比例尚且不足5%。截至收盘，跌38.41%，报7.65港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSI","BK1233","BK1574","513600","HSCEI","IE00BZ08YT58.USD","SG9999002828.SGD","02833","IE00BZ08YS42.EUR","BK1515","BK1606","09658","MCHmain","09939","159938","BK1191","BK1161","HSTECH","BK1521","BK1526","02566","02877","80175","IE00B0JY6N72.USD","00175","BK1589","BK1104","LU0315179316.USD","HHImain","BK1612","BK1119","BK1531","BK1539","09966","YANG","IE00BZ08YR35.GBP","00434","GELYY","EVS.SI"],"gpt_icon":1},{"id":"1196982240","title":"异动解读 | 康宁杰瑞制药-B盘中大跌7.37% 产品销售承压或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1196982240","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196982240?lang=zh_cn&edition=full","pubTime":"2024-11-28 14:40","pubTimestamp":1732776032,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B股票11月28日出现7.37%的盘中大跌,引发市场关注。\n\n根据相关报导,分析称公司主要产品销售可能短期承压,机构将其明年收入预测大幅下调。报告表示,行业合规整治影响恩维达销售、部分在研药物上市节奏推迟,导致下调公司2025年收入预测至4.50亿元。同时机构还下调了恩维达和KN046的经POS调整销售峰值。\n\n作为一家从事生物制药业务的上市公司,康宁杰瑞主要研发和销售肿瘤免疫类药物。如果主力产品销售短期承压,可能会严重影响其营收和现金流,令投资者对公司未来前景产生担忧。综合而言,公司产品销售前景欠佳或是导致本次股价大跌的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09966"],"gpt_icon":0},{"id":"2486535088","title":"港股异动 | 康宁杰瑞制药-B(09966)再跌超7% 机构称产品销售或短期承压 下调公司明年收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2486535088","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486535088?lang=zh_cn&edition=full","pubTime":"2024-11-28 14:34","pubTimestamp":1732775673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B午后跌超7%，截至发稿，跌7.37%，报3.77港元，成交额1556.04万港元。交银国际发布研报称，下调康宁杰瑞制药-B目标价至5港元，维持“中性”评级。该行预计KN026和JSKN003有望在国内合计产生近50亿元的峰值销售额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2486035338","title":"康宁杰瑞制药-B(09966)下跌5.16%，报3.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035338","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035338?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:56","pubTimestamp":1732766165,"startTime":"0","endTime":"0","summary":"11月28日，康宁杰瑞制药-B(09966)盘中下跌5.16%，截至11:56，报3.86元/股，成交602.53万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/28115645784849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2486353433","title":"康宁杰瑞制药-B盘中异动 大幅跳水5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486353433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486353433?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:56","pubTimestamp":1732766163,"startTime":"0","endTime":"0","summary":"2024年11月28日临近午盘11时56分，康宁杰瑞制药-B股票出现波动，股价大幅下挫5.16%。截至发稿，该股报3.860港元/股，成交量152.301万股，换手率0.16%，振幅5.90%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。康宁杰瑞制药-B股票所在的生物技术行业中，整体跌幅为0.66%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家投资控股公司,主要从事生物制药业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128115603971a905d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128115603971a905d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2486355362","title":"康宁杰瑞制药－Ｂ(09966)股价下跌5.16%，现价港币$3.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2486355362","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486355362?lang=zh_cn&edition=full","pubTime":"2024-11-28 11:56","pubTimestamp":1732766160,"startTime":"0","endTime":"0","summary":"[下跌股]康宁杰瑞制药－Ｂ(09966) 股价在上午11:56比前收市价下跌5.16%，现股价为港币$3.86。至目前为止，今日最高价为$4.1，而最低价为$3.86。总成交量为150.901万股，总成交金额为港币$597.113万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2411281331/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2486269867","title":"港股异动 | 康宁杰瑞制药-B(09966)跌近4% 机构下调恩维达和KN046的经POS调整销售峰值","url":"https://stock-news.laohu8.com/highlight/detail?id=2486269867","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486269867?lang=zh_cn&edition=full","pubTime":"2024-11-27 11:21","pubTimestamp":1732677690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B跌近4%，截至发稿，跌3.91%，报3.91港元，成交额1295.09万港元。该行预计KN026和JSKN003有望在国内合计产生近50亿元的峰值销售额。该行表示，上调康宁杰瑞制药2024年收入预测至6.57亿元人民币(下同)，以反映JSKN003授权合作的相关首付款，但考虑到行业合规整治影响恩维达销售、个别在研药物上市节奏推迟，下调2025年收入预测至4.5亿元，并下调恩维达和KN046的经POS调整销售峰值至11亿及5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2486644878","title":"交银国际：维持康宁杰瑞制药-B“中性”评级 目标价下调至5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486644878","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486644878?lang=zh_cn&edition=full","pubTime":"2024-11-27 10:46","pubTimestamp":1732675560,"startTime":"0","endTime":"0","summary":"　　交银国际发布研究报告称，下调康宁杰瑞制药-B目标价至5港元，维持“中性”评级。该行预计KN026和JSKN003有望在国内合计产生近50亿元的峰值销售额。　　该行表示，上调康宁杰瑞制药2024年收入预测至6.57亿元人民币（下同），以反映JSKN003授权合作的相关首付款，但考虑到行业合规整治影响恩维达销售、个别在研药物上市节奏推迟，下调2025年收入预测至4.5亿元，并下调恩维达和KN046的经POS调整销售峰值至11亿及5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-11-27/doc-incxnmtq6834612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09966"],"gpt_icon":0},{"id":"2486986313","title":"【券商聚焦】交银国际削康宁杰瑞制药(09966)目标价32.4% 指产品销售短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2486986313","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486986313?lang=zh_cn&edition=full","pubTime":"2024-11-27 09:20","pubTimestamp":1732670411,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指，康宁杰瑞制药 HER2 管线产品矩阵成型中，巨大商业化价值待兑现：1）JSKN033的I期数据在SITC大会上首次公布并入选LBA，显示在HER2表达或HER2 突变的NSCLC患者中达到80%的DCR。该行预计KN026和JSKN003有望在中国合计产生近50亿元的峰值销售额。同时，该行大幅下调2024-25 年研发和销售费用预测。最后，该行上调 WACC 至12.0%，得到最新的DCF目标价5.00港元，对应16%未来12个月潜在升幅，维持中性评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948466","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"gpt_icon":0},{"id":"2486104652","title":"康宁杰瑞制药-B(09966)下跌5.09%，报4.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486104652","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486104652?lang=zh_cn&edition=full","pubTime":"2024-11-26 14:25","pubTimestamp":1732602323,"startTime":"0","endTime":"0","summary":"11月26日，康宁杰瑞制药-B(09966)盘中下跌5.09%，截至14:25，报4.1元/股，成交1258.28万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/26142545682296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1161","09966"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":-0.0514},{"period":"1month","weight":-0.2235},{"period":"3month","weight":0.3195},{"period":"6month","weight":0.3605},{"period":"1year","weight":-0.4472},{"period":"ytd","weight":-0.4714}],"compareEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":0.0045},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.0956},{"period":"1year","weight":0.1889},{"period":"ytd","weight":0.1587}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家投资控股公司，主要从事生物制药业务。公司专注于研发、生产和商业化创新肿瘤免疫生物大分子靶向药物的全产业链企业。公司拥有生物创新药开发技术平台，包括蛋白质工程平台、多功能抗体开发平台和抗体筛选平台。该公司在海内外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.131218},{"month":2,"riseRate":0.6,"avgChangeRate":0.11167},{"month":3,"riseRate":0,"avgChangeRate":-0.116679},{"month":4,"riseRate":1,"avgChangeRate":0.117691},{"month":5,"riseRate":0.4,"avgChangeRate":-0.096701},{"month":6,"riseRate":0.4,"avgChangeRate":0.026634},{"month":7,"riseRate":0.2,"avgChangeRate":-0.0532},{"month":8,"riseRate":0.4,"avgChangeRate":0.041129},{"month":9,"riseRate":0.2,"avgChangeRate":0.094086},{"month":10,"riseRate":0.4,"avgChangeRate":-0.004359},{"month":11,"riseRate":0.6,"avgChangeRate":0.064609},{"month":12,"riseRate":0.6,"avgChangeRate":-0.00357}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}